Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer

BACKGROUND: To determine the maximum tolerated dose (MTD) and safety, and explore efficacy and biomarkers of vandetanib with cetuximab and irinotecan in second-line metastatic colorectal cancer. METHODS: Vandetanib (an orally bioavailable VEGFR-2 and EGFR tyrosine kinases inhibitor) was combined at...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Meyerhardt, Jeffrey A., Ancukiewicz, Marek, Abrams, Thomas A., Schrag, Deborah, Enzinger, Peter C., Chan, Jennifer A., Kulke, Matthew H., Wolpin, Brian M., Goldstein, Michael, Blaszkowsky, Lawrence, Zhu, Andrew X., Elliott, Meaghan, Regan, Eileen, Jain, Rakesh K., Duda, Dan G.
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2012
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3373492/
https://ncbi.nlm.nih.gov/pubmed/22701615
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0038231
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki